GSK, Elegen collaborate on cell-free DNA for vaccines and medicines
The multi-year collaboration allows GSK to leverage Elegen’s cell-free synthetic DNA production technology, in exchange for up to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Jan 24
The multi-year collaboration allows GSK to leverage Elegen’s cell-free synthetic DNA production technology, in exchange for up to…
25 Jan 24
New developments in the biopharmaceutical field fuel a need for highly scalable and flexible solutions
16 Jan 24
PanDNA is designed to expand the array of sample types suitable for long-read sequencing, including cells, bacteria, blood,…
11 Jan 24
XeriJect formulations are innovative, ready-to-use, viscoelastic pharmaceutical suspensions that have the potential to improve drug delivery, lower treatment…
13 Dec 23
The acquisition will strengthen AstraZeneca’s vaccines and immune therapies pipeline with Icosavax’s lead investigational vaccine candidate IVX-A12, a…
11 Dec 23
BioNTech will build and operate a clinical-scale mRNA manufacturing facility leveraging its digitally enabled modular manufacturing units, the…
29 Aug 23
Abcam, a UK-based provider of protein-based antibodies, reagents, biomarkers, and assays, will operate as a standalone company and…
14 Aug 23
As part of the collaboration, Logomix will initially contribute genome editing capabilities to assist HebeCell in creating the…
11 Aug 23
The investment will help Astellas to establish a significant presence in life science innovation hotspots in the world…
14 Jul 23
The acquisition allows Applied DNA Sciences to leverage its LinearDNA platform, which enables efficient chemical modification of DNA…